Lv1
40 积分 2024-03-17 加入
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1天前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
2天前
已完结
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
1个月前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
2个月前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
2个月前
已完结
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
3个月前
已完结
Interleukin-18 Regulates Both Th1 and Th2 Responses
3个月前
已完结
Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules
3个月前
已完结
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC
4个月前
已完结
Relocalizing transcriptional kinases to activate apoptosis
4个月前
已完结
皖公网安备34019202002308
